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National Aspergillosis Centre, University Hospital of South Manchester and The University of Manchester, Manchester, UKAbstractEstimates of the incidence and prevalence of serious fungal infections, based on epidemiological data, are essential in order to inform public
health priorities given the lack of resources dedicated to the diagnosis and treatment of these serious fungal diseases. However, epidemiology
of these infections is largely unknown, except for candidaemia and cryptococcosis. The aim of this work is to calculate the burden of serious
fungal infections in Spain. All published epidemiology papers reporting fungal infection rates from Spain were identiﬁed. Where no data
existed, we used speciﬁc populations at risk and fungal infection frequencies in those populations to estimate national incidence or
prevalence, depending on the condition. Around 8.1 million people suffer a fungal infection every year. Most of them are skin or mucosal
infections causing no deaths. Candidaemia is more common than in other European countries and has risen by 1.88-fold in frequency in
the last decade (8.1 cases × 100 000). Good estimates of invasive aspergillosis (2.75 cases × 100 000) and mucormycosis
(0.04 × 100 000) are available. Fungal infections with a high mortality such as invasive aspergillosis, candidaemia, Pneumocystis pneumonia
and mucormycosis are not numerous in Spain, but they affect those with severe underlying diseases and are therefore linked to poor
outcomes. Additional studies are required, especially for high burden diseases such as recurrent thrush in women (~9000
cases × 100 000 women), allergic bronchopulmonary aspergillosis (126 cases × 100 000) and severe asthma with fungal sensitisation (198
cases × 100 000).
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E-mail: jlrtudela@gmail.comIntroductionEpidemiology of fungal infections is largely unknown except for
candidaemia and cryptococcosis where some population-basedClinical Microbiology and Infection © 2014 European Society of Csurveillance studies have been published [1,2]. Global estimates
of cutaneous fungal infections, invasive fungal infections, chronic
pulmonary aspergillosis after pulmonary tuberculosis, and
sarcoidosis and allergic bronchopulmonary aspergillosis
complicating asthma have recently been published [3–7]. Apart
from the mildest cutaneous and mucosal fungal infections, most
are serious, causing a high mortality and morbidity that increase
if they are not suspected, diagnosed and treated as quickly as
possible. Estimates of the incidence and prevalence of seriousClin Microbiol Infect 2015; 21: 183–189
linical Microbiology and Infectious Diseases. Published by Elsevier Ltd. All rights reserved
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order to inform public health priorities given limited resources
to diagnose and treat these diseases.
The aim of this work is to calculate the burden of serious
fungal infections in Spain, a country with an estimated popula-
tion of 47 million. Such an estimate of fungal burden has not
previously been attempted in this country.Material and methodsAll published epidemiology papers reporting fungal infection
rates from Spain were identiﬁed. Where no data existed, we
used speciﬁc populations at risk and fungal infection frequencies
in those populations to estimate national incidence or preva-
lence, depending on the condition.
2010 population statistics were derived from the Statistics
National Institute (http://www.ine.es/).
Prevalence of skin fungal diseases was obtained from Vos
et al. [3].
The number of women aged between 14 and 55 years was
obtained from the National Statistics Institute (http://www.ine.
es). A 9% rate of recurrent vulvovaginal candidiasis was used
and ‘recurrent’ deﬁned as at least four episodes per year [8].
The number of HIV/AIDS patients in Spain was taken from
epidemiologic surveillance of AIDS [9,10]. The proportion of
HIV-infected patients receiving antiretroviral therapy (ARV)
was estimated from the PISCIS cohort [11,12]. The annual new
AIDS cases, the proportion of AIDS patients presenting with
Pneumocystis pneumonia (PCP) or with cryptococcal meningitis
and AIDS-related deaths in 2010 were obtained from the CoRIS
cohort [13].
The number of pulmonary tuberculosis (PTB) cases was
obtained from the National Registry [14]. Using the approach
taken in Denning et al. [4], the 5-year point prevalence of
chronic pulmonary aspergillosis (CPA) following PTB was
estimated, assuming a 12% cavitation rate following therapy [4].
Further, it was assumed that PTB was the underlying diagnosis
of CPA in 25% of cases (slightly higher than that of Smith &
Denning [15], but lower than in France [16]).
The number of people with chronic obstructive pulmonary
disease (COPD) was ascertained nationally [17] and a regional
estimate of the number of admissions with COPD obtained
from Andalusia [18], recently conﬁrmed by the Organisation
for Economic Co-operation and Development statistics [19].
Asthma rates in adults (children were not included for risk
estimation) were obtained from multiple sources [20–24] and a
mean of 7% of the adult population was used for estimates. The
risk of allergic bronchopulmonary aspergillosis (ABPA) compli-
cating asthmawas estimated at 2.5% based on ﬁve previous studiesClinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and Infect[6]. The rate of severe asthmawith fungal sensitisation (SAFS) was
estimated as the worst 10% of the total asthma population, of
whom at least 33% have fungal sensitisation [25].
Cystic ﬁbrosis numbers were obtained from the European
registry of the European Cystic Fibrosis Society and the Spanish
Scientiﬁc Society of Cystic Fibrosis (https://www.ecfs.eu/ﬁles/
webfm/webﬁles/File/ecfs_registry/ECFSPR_Report0809_
v32012.pdf).
Incidence and prevalence of haematological diseases were
taken from Globocan 2008 (http://globocan.iarc.fr) and the
Spanish Registry of Leukaemia and Lymphomas (http://www.
leucemiaylinfoma.com/resources/ﬁles/f9412075-9481-479b-
a8ef-81c4fd333152.pdf). Percentages of invasive aspergillosis
(IA) in this population were taken from a study performed in
Italy in 2004 [26]. Italy is a neighbouring Mediterranean country,
and the haematological diseases ﬁgures are similar in the Glo-
bocan database (http://globocan.iarc.fr).
The rate of IA in critical care was assumed to be all attrib-
utable to COPD, and the Madrid-based study showed that 1.3%
of COPD admissions developed IA in the ﬁnal year, based on
culture with support from serum (but not respiratory) gal-
actomannan in a few patients [27].
The number of transplants was obtained from the Spanish
National Organization for Transplantation (http://www.ont.es/
infesp/Paginas/Memorias.aspx). The incidence of invasive
aspergillosis in solid organ-transplanted patients was taken
from different studies [28–31]. PCP cases in non-AIDs pa-
tients were derived from Calderón et al. as a population es-
timate was provided, 3.4 cases per 100 000 [32]. Cases in
AIDs patients were calculated using data obtained in the CoRIS
study [13].
Candidaemia cases were estimated from a population-based
surveillance study recently performed in Spain [33]. The
number of critical care beds in Spain in 2010 was obtained
from the intensive care units registry (http://www.msssi.gob.
es/organizacion/sns/planCalidadSNS/docs/UCI.pdf); 35.1% of
candidaemia cases were among patients admitted to the
intensive care unit (ICU) [33]. The annual number of cases of
Candida peritonitis following surgery and ratio to candidaemia
was assumed to be the same as in France, as there are no data
from Spain, and as it is a neighbouring country we expect the
number to be similar to that in Spain [34]. Candida peritonitis
complicating chronic ambulatory peritoneal dialysis was not
estimated.
For mucormycosis, we used a rate of 0.43 cases per 1 million
inhabitants, as previously documented [35].
The annual incidence of histoplasmosis was calculated after
reviewing the records of the Mycology Reference Laboratory
for the last 5 years. Most of the cases identiﬁed in Spain are
diagnosed or conﬁrmed in this laboratory [36].ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 183–189
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Spain is a country with an estimated population of 47 million
people; 49.4% are men and 15% are children 14 years old
(http://www.ine.es/). The estimated number of HIV-infected
patients ranged between 130,000 and 150,000 people (num-
ber set to 140,000 for calculation purposes) [10]. The number
of HIV-infected patients without ARVs was estimated according
to Ambrosioni et al. [12] as 44% of the total HIV population
(61,600 people). Table 1 shows the total burden of fungal in-
fections, the number of infections classiﬁed according to the
main risk factors, as well as the rate for 100 000 inhabitants.
Skin fungal infections
These are the most prevalent fungal infections in Spain. Using
the global prevalence of 14.3% estimated by Vos et al. [3],
6 721 000 Spanish inhabitants would have a skin fungal infection
(Table 1). Recently, the Global Burden of Disease estimates [3]
placed cutaneous fungal infections as the fourth most common
health problem (after dental caries and headaches), with about
1 billion affected worldwide. In 2010, skin fungal diseases were
estimated to lead to a mean of 2 303 000 years lived with
disability (YLDs) or 33 YLDs per 100 000 inhabitants, a signif-
icant number when compared with many other infectious dis-
eases already included in the Health Programs of International
Agencies.
Mucosal infections
Recurrent vaginal thrush, deﬁned as at least four episodes every
year, is also very prevalent in Spain. As many as 1 189 238
Spanish women between 14 and 55 years of age get recurrent
vaginal thrush every year (Table 1). The rate of recurrentTABLE 1. Burden of fungal diseases in Spain according the main ri
Number of infections per underly
None HIV/AIDS R
Fungal skin diseases 6 721 000 – –
Oral candidiasis – 55 440 –
Oesophageal candidiasis – 16 240 –
Candidaemia – – –
Candida peritonitis – – –
Recurrent vaginal candidiasis (4×/year or more) 1 189 238 – –
Allergic bronchopulmonary aspergillosis – – 59
Severe asthma with fungal sensitization – – 93
Chronic pulmonary aspergillosis – – 43
Invasive aspergillosis – – –
Mucormycosis 20 – –
Cryptococcal meningitis – 12 –
Pneumocystis pneumonia – 97 –
Histoplasmosis – 10 –
Total burden estimated 7 910 258 67 212 15
ICU, intensive care unit.
aRate of annual candidaemia in Spain according to a recent study [29] is 8.1 per 100 000 inh
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiologythrush is slightly higher in those in their 20 s, but continues to
beyond menopause in a few women [8]. This translates into an
annual incidence of ~9000 cases per 100 000 women (Table 1).
In HIV infection, oral candidiasis is estimated to occur at least
once in 90% of those without ARVs, and oesophageal candidi-
asis in 20% of patients without ARVs and 5% of patients on
ARVs [37–39]. Therefore, 55 440 cases of oral candidiasis and
16 240 of oesophageal candidiasis are expected annually
(Table 1). The number of oral or oesophageal candidiasis
related with cancer or transplanted patients are unknown in
Spain. There are no ofﬁcial records and we have found no
published studies about incidence or prevalence in this setting.
Respiratory infections
In Table 2 the number of IA in allogeneic (haematopoietic stem
cell transplantation) and solid organ-transplanted patients is
shown. One hundred seventy-two cases of IA were estimated
in allogeneic and solid organ-transplanted patients. We assumed
that IA (proven and probable) occurred in 10% of haemato-
poietic stem cell transplantation, 6% of heart, 4% of lung and
liver, and 1% of kidney-transplanted patients [31]. Much higher
rates of colonisation and tracheobronchitis are found in lung
transplant recipients, but we have discounted these to focus on
IA only. Infrequent transplantation procedures, such as small
bowel and pancreas, have also been ignored in these estimates.
Haematological diseases are another important risk factor
for IA. In 2010, there were a total of 15 919 leukaemias, lym-
phomas, and multiple myeloma cases in Spain (http://www.
leucemiaylinfoma.com/resources/ﬁles/f9412075-9481-479b-
a8ef-81c4fd333152.pdf). Table 3 shows the incidence, preva-
lence, and the number of IA cases. The highest incidence of IA
was among acute myeloid leukaemia patients, where 148 cases
were estimated. IA in other haematological conditions is
limited, and for some of them the incidence is unknownsk factors
ing disorder per year
Total burden Rate /100 Kespiratory Cancer/Tx ICU
– – 6 721 000 14 300
– – 55 440 117.96
– – 16 240 34.55
– 1336 3807a 8.1
– 668 668 1.42
– – 1 189 238 9000
210 – – 59 210 126
044 – – 93 044 198
18 – – 4318 9.19
419 874 1293 2.75
– – 20 0.04
– – 12 0.03
208 – 305 3.40
– – 10 0.02
6 572 627 2878 8 144 605
abitants, consistent with 3807 cases.
and Infectious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 183–189
TABLE 2. Burden of invasive aspergillosis in allogeneic
transplanted patients and solid organ transplanted populations
Underlying disease Number of cases in 2010 Number of IA
Allogeneic HSCT 866 87
Renal transplant 2225 22
Lung transplant 235 9
Heart transplant 243 15
Liver transplant 971 39
Total 4540 172
HSCT, haematopoietic stem cell transplantation; IA, invasive aspergillosis.
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Therefore, in transplanted and haematological disease patients,
a total of 419 cases of IA are expected annually.
Finally, in critical care, 874 cases were calculated, most with
COPD. It was assumed that 1.3% of COPD cases admitted to a
hospital have or develop IA, based on a prospective study from
Madrid [18]. Other conditions associated with IA in this setting,
such as severe hepatic or autoimmune disease, have been ignored
for these estimates, although a recent study from Hangzhou
documented a 5% IA rate in acute-on-chronic hepatic failure [40].
Among the causes of CPA are COPD, sarcoidosis, ABPA,
prior pneumothorax, rheumatoid arthritis, PTB and non-
tuberculous mycobacterial infection. PTB is an infrequent cause
of CPA in Europe. In 2010, there were 5351 cases of PTB in
Spain, most in HIV-negative people; 342 new cases of CPA are
expected annually, with a 5-year period prevalence of 1079 cases
(assuming 15% annual mortality or surgical resection). Taking
into consideration the other more frequent causes of CPA cases,
such as COPD, sarcoidosis, ABPA, prior pneumothorax, rheu-
matoid arthritis and nontuberculous mycobacterial infection
[15], a total of 4318 total CPA cases are estimated, assuming that
PTB patients account for only 25% of CPA cases (Table 1).
Estimates of asthma prevalence in adults are between 5% and
8%, and assuming that 2.5% of asthmatics have ABPA, 59 210
adults with ABPA are likely, and 93 044 with SAFS (Table 1).TABLE 3. Burden of invasive aspergillosis in patients with haemato
Haematological disease Incidence 3 100 000a 5 year prevalen
Leukaemia 10.6 22.5
Acute myeloid leukaemia + MDS 4.44 9.43
Acute lymphoblastic leukaemia 1.14 2.43
Chronic myeloid leukaemia 0.67 1.42
Chronic lymphatic leukaemia 3.63 7.7
Other acute leukaemiasc 0.21 0.45
Unclassiﬁedc 0.51 1.08
Multiple myeloma 6.47 15.31
Hodgkin lymphoma 2.50 8
Non-Hodgkin lymphoma 14.30 38
Total
IA, invasive aspergillosis; MDS, myelodysplastic syndrome.
aGlobocan 2008 (http://globocan.iarc.fr).
bPagano et al. [26].
cOther acute leukaemias include: acute biphenotypic, T granular cells, mast cell, NK cells.
Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectChildren were not taken into account for these estimates
because both ABPA and SAFS appear to be very rare in
childhood. No estimate of prevalence exists, and therefore,
applying the adult rates will greatly overestimate the total rates.
The annual incidence of Pneumocystis pneumonia according
to Calderón et al. [32] is 3.4 cases per 100 000, consistent with
1598 cases annually in Spain. Most of the cases (87%) occurred
in HIV-positive patients (Table 1). The CoRIS [13] cohort, a
more recent study dealing only with HIV patients, showed that
only 97 cases of PCP are expected in this population. One
reason for the different number of cases of PCP presented in
the two studies analysed [13,32] might be the time passed be-
tween them (1998–1999 vs. 2004), highlighting the need to
perform epidemiologic surveillance in order to allocate the
right budget to control every disease. Because of the lack of
data for other non-HIV populations at risk, we have used
Calderón’s rate to calculate PCP’s incidence [32].
Candidaemia
A population-based survey performed in Barcelona in
2002–2003 [41] showed a rate of 4.3 candidaemia cases per
100 000 inhabitants. However, a more recent study [33] per-
formed in 2010–2011 in ﬁve areas of Spain reported an annual
candidaemia rate of 8.1 per 100 000 inhabitants. This means
that the incidence has almost doubled in approximately 10
years. This rate is similar to the one found in Denmark (8.6
cases per 100 000 inhabitants) [1], but higher than other Eu-
ropean countries such as Norway or Finland (3–5 cases per
100 000 inhabitants) [42,43]. In the United States, comparable
rates were found in some states (6–8 cases per 100 000), while
others showed higher rates, with up to 20 cases per 100 000
inhabitants [44]. As 35.1% of all candidaemias occurred in an
ICU, 1336 cases are expected annually in Spain (Table 1).
There is one case of candida peritonitis for every two ICU
patients with candidaemia [34], so we estimated 668 cases,
most postoperative.logical diseases
ce 3 100 000a Cases in 2010 % of IAb Annual cases of IA
4982
2088 7.11 148
538 3.87 21
314 2.07 6
1704 0.36 6
100 ? –
239 ? –
3041 0.27 8
1175 0.31 4
6721 0.81 54
15 919 247
ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 183–189
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Of the 130,000–150,000 estimated HIV-positive patients, 12
(0.8%) of 1500 new AIDS cases each year develop cryptococcal
meningitis [13]. Other cases of cryptococcal meningitis occur, but
we have no reliable means to estimate this. For mucormycosis, a
Spanish study found an incidence rate of 0.04 cases per 100 000
inhabitants that suggests 20 cases every year [35]. However, in
France, a neighbouring country, the incidence recently found was
0.12 cases per 100 000 inhabitants. For histoplasmosis, incidence
can be estimated in 10 new cases per year [36].ConclusionsThe epidemiology and burden of most fungal infections in Spain
is well documented for many infections. Candidaemia is more
common than in other European countries and has risen by
almost twofold in frequency in the last decade. Good estimates
of PCP, invasive aspergillosis complicating COPD, recurrent
vulvovaginal candidiasis and mucormycosis have also been
determined in Spain, although in some cases the data are old
and some discrepancies in the number of cases between studies
were found. Clearly, additional studies are required, especially
for high burden diseases such as APBA and SAFS. Globally there
are 350,000 asthma deaths, most in adults, and many of these
will be in those with SAFS [3]. The underlying disease proﬁle of
sequentially diagnosed chronic pulmonary aspergillosis and
annual mortality would be helpful in determining the national
burden of this debilitating disease.
Apart from cutaneous fungal infections and Pneumocystis
pneumonia, most fungal infections are not transmitted from
person to person. Most are acquired from the environment or, in
the case of Candida, from endogenous (gut) ﬂora. Most pathogenic
fungi are therefore unavoidable. No vaccines are available.
As no fungal infection is considered notiﬁable, the current
records rely on epidemiologic studies performed in one or
more institutions. However, for many fungal diseases, the rates
have been calculated based on the frequency of fungal infections
in patients at risk. In addition, there is no information about
YLDs for fungal disease that is usually not fatal, a crucial
parameter in the promotion and monitoring of health.
Around 8.1 million people suffer a fungal infection in Spain
every year. Most of them are skin ormucosal infections causing no
deaths. However, the number of YLDs of skin fungal infections is a
matter of concern. Fungal infections with a high mortality, such as
IA, candidaemia, PCP and mucormycosis, are not numerous in
Spain (6718 annual cases), but they affect those with severe un-
derlying diseases and are therefore linked to poor outcomes.
LIFE (www.LIFE-worldwide.org) has launched an initiative in
many countries to calculate the burden of fungal diseases followingClinical Microbiology and Infection © 2014 European Society of Clinical Microbiologya similar approach.Wewill obtain some preliminary data in order
to ascertain the public health importance of fungal diseases in
many of these countries. This will facilitate the undertaking of
better epidemiologic studies, which will inform public health pri-
orities. Currently, inadequate resources are applied tomost fungal
infections and so could be considered “neglected diseases,”
although they are not currently designated as such.
As a matter of concern, it is estimated that worldwide deaths
attributed to fungal infections (>1 350 000) [5] are as high as
those of tuberculosis (1 400 000) and malaria (1 240 000) [45],
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